SA4503 Low

DRUG2 trials

Sponsors

M's Science Corporation

Conditions

Depressive Disorder, MajorIschemic Stroke

Phase 2

SA4503 8-Week Study in Major Depressive Disorder (MDD)

CompletedNCT00551109

M's Science CorporationDepressive Disorder, Major

Start: 2007-11-30End: 2008-09-30Target: 150Updated: 2008-12-18

Safety and Preliminary Efficacy Study of SA4503 in Subjects Recovering From Ischemic Stroke

CompletedNCT00639249

M's Science CorporationIschemic Stroke

Start: 2008-02-29Updated: 2009-07-29

Related Papers

Phase II Trial of the Sigma-1 Receptor Agonist Cutamesine (SA4503) for Recovery Enhancement After Acute Ischemic Stroke

Stroke2014-10-0182 citations